Onco Actu du 3 avril 2020

	1. BIOLOGIE
Suspect cells’ ‘neighbor’ implicated in colorectal cancer [Yale] Now scientists at Yale and collaborators in Greece have found that some unprepossessing neighbors of those stem cells actually harbor a molecular villain that can jump-start cancers of the colon, they report in the journal Nature.
	2.5 ETIOLOGIE - GÉNOME
Cancer Researchers Discover Novel Inherited Mutation Predisposing Children to Medulloblastoma [Genome Web] They found that ELP1 was the most common medulloblastoma predisposition gene, and increased the prevalence of genetic predisposition among pediatric patients with that particular subgroup to 40 percent.
	3. PRÉVENTION
How Can We Reduce the Risk for Esophageal Cancer? [Cancer Research Catalyst] Esophageal cancer is relatively difficult to diagnose. If caught early, which happens in less than 20 percent of patients, the five-year survival rate is about 46.7 percent. For the roughly 40 percent of patients who are diagnosed when the disease has spread, five-year survival is a dismal 4.8 percent.
	5.1 TRAITEMENTS - PRÉ-CLINIQUE
Tailoring an anti-cancer drug for optimal tumor cell killing [University of Montreal] In a study published this week in Science, Université de Montreal researchers report key structural and biochemical differences among a class of anti-cancer drugs known as PARP inhibitors. The research resolves a long-standing and perplexing quandary over differences between the effectiveness of PARP inhibitors used in cancer clinics.
Starving Pancreatic Cancer of Cysteine May Kill Tumor Cells [Columbia University] The compound starves tumors of an amino acid, cysteine, which was found to be critical to the survival of pancreatic cancer cells. The study, conducted in mice with pancreatic cancer, was published online today in the journal Science.
	5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
Gilead's Kite taps Teneobio to build next-gen CAR-Ts for multiple myeloma [Fierce Biotech] The advantage of that approach? It could allow the development of CARs that target more than one antigen, potentially cutting down on relapse rates.
J&J gives pioneering stem cell biotech its first Big Pharma deal, partnering on iPSC CAR-T and CAR-NK [EndPoints] Late last summer, one of the earliest stem cell therapy companies got two government decisions in the span of three weeks: The USPTO granted them a patent for iPSC-derived CAR-T cells, and then the FDA cleared them for their first-in-human CAR-NK trial.
Kite Licenses Antibodies and Establishes Collaboration With Teneobio in Multiple Myeloma [Gilead] Kite and Teneobio will Collaborate on Next-Generation Dual-Targeting CAR T Therapies in Multiple Myeloma Utilizing UniAb® Antibodies.
	5.12.5 IMMUNOTHÉRAPIES - PHARMA
Merck looks for leg up on Bristol with Keytruda's latest colorectal cancer win [Fierce Pharma] As Merck was quick to note, the trial, Keynote-177, was the first phase 3 trial to successfully pit a single-agent therapy against the standard of care—a combination of Roche’s Avastin and a chemo regimen known as mFOLFOX6.
Merck scores new advance on tumor-agnostic front as Keytruda beat chemo-based regimens in a type of colorectal cancer [EndPoints] A PFS win, though, doesn’t guarantee success on the OS front, as the painful setback in KEYNOTE-604 (extensive-stage small cell lung cancer, or ES-SCLC) showed.
	5.2 PHARMA
Pfizer Receives European Approval for Oncology Biosimilar, RUXIENCE™ (rituximab) [Pfizer] The EC approval is based on a comprehensive data package which demonstrated biosimilarity of RUXIENCE to the reference product
	6.15 LUTTE CONTRE LES CANCERS - COVID-19
Testing for COVID-19 coronavirus at the Francis Crick Institute [Cancer Research UK] “Two weeks ago, it was clear to me that we didn’t have COVID-19 testing at the hospital and we needed it,” says Professor Charlie Swanton, Cancer Research UK’s chief clinician, who spearheaded the transformation with Steve Gamblin, the Crick’s research director, in just 2 weeks.
As Coronavirus Strains Hospitals, Cancer Patients Face Treatment Delays, Uncertainty [NPR] At the American Cancer Society, Deputy Chief Medical Officer Dr. Len Lichtenfeld is hearing from patients across the country who are having their chemotherapy delayed or surgery cancelled.